Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
IBZT
Is .06
IBZT
Virtural Trading how cool
Thanks Subs found IBZT
You guys rock!
IBZT
15 BAGGER :)
Not letting this one go
TY Dallas
Good day
Gm Subs
Where can I get thoses e-mail alerts? and is their any charge?
BTW thanks for IBZT that I found here from .0027 still holding.
Have a good day ladies and gents.
Thanks Capt_Nemo,
For being so kind in answering my ?'s
and for the welcome,this board >>> "RULES"
Happy New Year
and a prosperous one at that for all subs.
I do have a question if one of you would be so kind?
If a company has 5 billion shares authorized and only has like 1.4 common out is this common place have so many to issue?? to dilute if need be?? and to protect them from being bought out?
TIA
IBZT had News late last night.
Press Release Source: iBIZ Technology Corp.
iBIZ Technology Corp. Is Covered On CNBC
Wednesday December 31, 12:25 pm ET
iBIZ's Virtual Laser Keyboard Is Featured in CNBC's Tech Watch Segment
PHOENIX, Dec. 31 /PRNewswire-FirstCall/ -- iBIZ Technology Corp. (OTC Bulletin Board: IBZT - News), a leading manufacturer and distributor of accessories for personal digital assistants (PDA) and hand-held devices, was covered today at 11:20AM Eastern on the "Tech Watch" segment on CNBC.
ADVERTISEMENT
The iBIZ Virtual Laser Keyboard attaches to PDAs and projects the image of a full-size keyboard onto the surface of the desk where the PDA is placed, making it easy to input text without a physical keyboard.
Jane Wells, CNBC Correspondent, said the Virtual Laser Keyboard is "an accessory that embeds laser-emitting as lens, infrared matrix that is projected out to a flat surface ... as you type into it ... it reflects the image back to a small camera that sits inside of the device and it registers a character." Wells also said, "It even makes a little tapping noise to make the whole experience more life-like."
"There are no mechanical moving parts whatsoever in the Virtual Laser Keyboard," said Ken Schilling, President & CEO of iBIZ Technology Corp. "It provides a projected image that is the perfect portable input device for PDAs. It's similar in responsiveness to regular keyboards, but extremely futuristic looking."
iBIZ will exhibit and showcase the much anticipated Virtual Laser Keyboard at the International Consumer Electronics Show 2004 in Las Vegas from January 8th - January 11th, 2004.
The Virtual Laser Keyboard is compatible with Palm, Pocket PCs, laptops and desktop PCs. The Virtual Laser Keyboard will be available for $99.99 from major retailers, e-commerce sites, and iBIZ Technology's own e-commerce site in 1st quarter 2004. An upcoming version for cell phones will be available in 4th quarter 2004.
About iBIZ Technology:
iBIZ is a leading manufacturer and distributor of accessories for personal digital assistant (PDA) and hand-held devices. iBIZ is recognized for innovative, high-quality, competitively priced products available through major retailers. For more information on iBIZ products and services, please visit www.ibizpda.com , email sales@ibizcorp.com , or call 1-800 234-0707.
CMKM
Whats uP^^ with that.
IBZT
I'm holding since .0027
I plan on telling my grand kids about this one.
Happy New Year all
IBZT
Best Press a Otcbb ever had on
CNBC
IBZT
LOOK AT THE BOTTOM
here is the email to confirm. if this is a fake, several people on here sure have gone through a ton of trouble to bulll...#### us about 11:20 tomorrow.
From:"David, Ted (NBC, CNBC)" Add to Address
BookTo:"'collinsaw@yahoo.com'" Subject:RE: information
pleaseDate:Tue, 30 Dec 2003 17:02:51 -0500 [input] [input] [input] [input]
MORNING CALL Air TimeGuestBooking Info
10:20 AMAchuthan, Lakshman
Economic Cycle Research Institute
Managing Director Topic: Initial Claims / Year End Wrap
10:30 AMGoldstein, Mara
CIBC World Markets
Pharmaceutical Analyst, Executive Director Topic: Year End - Drug Stocks
10:50 AMBolling, Eric
Independent Oil Trader Topic: Oil Market
Studio:
11:20 AMWells, Jane
CNBC
Topic: Tech Watch: New Cow Tracking Technology, Virtual Computer Keyboard
It doesn't say Jane Wells
11:20 I would think est
Also watch ADIO
Cow tracking Tech :)
IBZT
I have the cnbc guest list were on.
11:20
IBZT
I knew 10 bagger
:))
IBZT
Goodbye Sub .02
Nice 10 bagger
I like to add one more to sponsor.
That would be IBZT which trades now at
.0071
Happy Holidays to you all.
thanks
IBZT
Sold all my IDNW to get into this Little gem.
FORG
Forg, won a law suit against Sony for 28 mill it worked for because they Own the Rights to the JPEG File
from what I understand.
Happy Holidays to all and thanks for the help
IBZT
Keep this one your watch list
I hear they are going to be aired on CNBC Dec 31 11:30am
Happy Holidays to you all here.
http://www.ibizpda.com/index.htm
STRU~ News
Struthers Actively Explores New Business Initiatives
via COMTEX
December 22, 2003
CHARLESTON, S.C., Dec 22, 2003 (BUSINESS WIRE) --
Struthers, Inc. (OTC Pink Sheets: STRU) announced today that the Company is actively considering several different business initiatives and proposed business combinations that have been presented to it over the past several weeks. The specific types of initiatives being pursued include both traditional bio-tech related activities and also other non-traditional types of business operations.
Multi-Pronged Approach
'The Company has adopted a multi-pronged approach to its business development activities', said Douglas Beatty, President/CEO. 'While on the one hand we are planning on leveraging our existing technology, licenses, patents and trademarks to the fullest extent possible, we are also entertaining other proposals which involve new types of revenue streams for the Company'. 'With the re-birth of the Company and the seating of our new Board of Directors it became clear to us that there were a number of new opportunities available to us - options that should be pursued.'
Dana Allen, Chairman, stated 'The revival of the Company has given us a great opportunity, to look at those things that remain which are of continuing value, but also to consider some new and innovative concepts which have been forwarded.'
A Re-defined Business Philosophy - Profitability and Growth
'At it's initial meeting on December 6, 2003, the Board of Directors adopted a new business philosophy for Struthers, Inc. - that any business activity we consider must first meet the twin parameters of high growth and profitability,'said Bertram Remley, Secretary/Treasurer. 'Our shareholders have seen quite enough money-losing propositions in the past - now is the time to focus on profitability. While we continue with our initiative to 'discover and recover'assets, we are also looking to add new high-growth and profitable business activities to our portfolio.'
Status of Negotiations
'Due to confidentiality constraints, we are unable to disclose the specifics of the business relationships that are currently under discussion, however we are hopeful of being able to enter into memorandums of understanding in the near future, with closings slated for the first quarter of 2004,'said Douglas Beatty, President/CEO. 'So far, our discussions have proceeded on an excellent schedule, aided by the full involvement of our Board.'
Visit our Website at http://www.struthers-inc.com/
SOURCE: Struthers, Inc.
Pfizer ~News
December 21, 2003 13:08
Pfizer to Acquire Esperion Therapeutics to Extend Its Research Commitment In Cardiovascular Disease
Jump to first matched term
NEW YORK and ANN ARBOR, Mich., Dec 21, 2003 /PRNewswire via COMTEX/ -- Pfizer Inc today announced it has entered into an agreement to acquire Esperion Therapeutics, Inc., a biopharmaceutical company focused on the development of high density lipoprotein (HDL) targeted therapies for the treatment of cardiovascular disease.
Pursuant to this agreement, Pfizer will commence a cash tender offer to acquire the shares of Esperion stock for $1.3 billion at a price of $35 per share, subject to certain conditions. This price represents a 54 percent premium over Esperion's average closing share price during the last 20 trading days.
Esperion Therapeutics brings a novel approach to the emerging area of HDL Therapy and reverse lipid transport for the acute treatment of cardiovascular disease. Recently, Esperion published positive Phase II results on a biopharmaceutical compound (ETC-216) that showed a statistically significant reduction in plaque volume in patients with acute coronary syndrome at the end of six weeks. Esperion also has a second biopharmaceutical compound, ETC-588, in Phase II and a number of early-stage compounds.
"By acquiring Esperion, we can bring our research capabilities to bear on an emerging new area which has potentially significant beneficial impact on patients", said Hank McKinnell, chairman and chief executive officer of Pfizer. "Epidemiologic data and drug intervention trials both support a strong correlation between higher HDL levels and improvements in morbidity and mortality."
"The acquisition will enable us to utilize Pfizer's skills and apply the resources necessary to develop our pipeline of compounds to benefit patients with atherosclerosis", said Roger Newton, president and chief executive officer of Esperion. "We are pleased to have the opportunity to work with the world leader in cardiovascular medicines to develop HDL-focused therapies."
The Pfizer product Lipitor is the world's most prescribed agent for reducing low density lipoprotein (LDL). Pfizer is also developing Lipitor/torcetrapib, which works by combining Lipitor with an agent that inhibits the action of cholesteryl ester transfer protein or CETP. Results of Phase II studies indicate that this combination may represent a significant advance in preventive cardiovascular medicine by enhancing the LDL-lowering effect of Lipitor while also increasing HDL or "good" cholesterol.
While both Lipitor and Lipitor/torcetrapib are chronic therapies, Esperion has three clinical compounds that are being developed as acute, hospital-based treatments to regress arterial plaque and thereby reduce morbidity and mortality in patients who have had a cardiovascular event.
Atherosclerosis, which is a leading cause of death from heart attack and stroke, occurs when there is a build-up of cholesterol-rich fatty areas called plaques in the arteries. The break-up and dispersal of these plaques can block the blood flow throughout the body, which can be fatal. It is estimated that atherosclerosis accounts for more than 75 percent of all deaths from cardiovascular disease.
"Pfizer is clearly committed to long-term cardiovascular research", said Dr. McKinnell. "We recognize that HDL control is an emerging area, and that early-stage development brings risk. However, we are confident that the rigorous and long-term clinical trials we plan to conduct will further scientific and medical understanding in this area, which will ultimately benefit patients."
Based in Ann Arbor, MI, Esperion was founded by a group of scientists who worked on the discovery and development of Lipitor. Esperion will operate as a division of the Pfizer Global Research and Development organization, and remain in Ann Arbor.
Lazard and Cadwalader, Wickersham & Taft advised Pfizer in the transaction. Lehman Brothers and Morgan, Lewis & Bockius advised Esperion. Esperion is listed on the Nasdaq National Market under the symbol "ESPR."
NOTICE TO READ TENDER OFFER DOCUMENTS:
THIS PRESS RELEASE IS NEITHER AN OFFER TO PURCHASE NOR A SOLICITATION OF AN OFFER TO SELL SECURITIES OF ESPERION THERAPEUTICS, INC. THE TENDER OFFER WILL BE MADE SOLELY BY AN OFFER TO PURCHASE AND RELATED LETTER OF TRANSMITTAL TO BE DISSEMINATED TO THE STOCKHOLDERS UPON THE COMMENCEMENT OF THE TENDER OFFER. ESPERION THERAPEUTICS, INC. STOCKHOLDERS ARE ADVISED TO READ the OFFER TO PURCHASE on schedule to THAT WILL BE filed by PFIZER INC. AND the SOLICITATION/RECOMMENDATION OF THE BOARD OF DIRECTORS OF ESPERION THERAPEUTICS, INC. ON SCHEDULE 14D-9 THAT WILL BE filed by ESPERION THERAPEUTICS, INC. with THE SECURITIES AND EXCHANGE COMMISSION WHEN THEY ARE AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. THE OFFER TO PURCHASE, THE SOLICITATION/RECOMMENDATION STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC WILL BE MADE AVAILABLE TO STOCKHOLDERS OF ESPERION THERAPEUTICS, INC. AT NO EXPENSE TO THEM. THESE DOCUMENTS WILL ALSO BE AVAILABLE WITHOUT CHARGE AT THE SECURITIES AND EXCHANGE COMMISSION'S WEBSITE AT WWW.SEC.GOV.
Safe Harbor Statement of Esperion Therapeutics, Inc.
The information contained in this press release includes "forward-looking statements." These forward-looking statements are often identified by words such as "hope," "may," "believe," "anticipate," "plan," "expect," "require," "intend," "assume" and similar expressions. Forward-looking statements speak only as of the date of this press release, reflect management's current expectations, estimations and projections and involve certain factors, such as risks and uncertainties, that may cause actual results, performance or achievements to be far different from those suggested by Esperion's forward-looking statements. These factors include, but are not limited to, risks associated with: uncertainty as to whether Esperion's acquisition by Pfizer will be completed, Esperion's ability to successfully execute its business strategies, including entering into strategic partnerships or other transactions if the transaction with Pfizer is not completed; the progress and cost of development of Esperion's product candidates; the extent and timing of market acceptance of new products developed by Esperion or its competitors; Esperion's dependence on third parties to conduct clinical trials for Esperion's product candidates; the extent and timing of regulatory approval, as desired or required, for Esperion's product candidates; Esperion's dependence on licensing arrangements and strategic relationships with third parties; clinical trials; manufacturing; Esperion's dependence on patents and proprietary rights; litigation, proceedings, investigations and other disruptions of management's time resulting from the acquisition of Esperion's common stock by various persons associated with Scott Sacane; the procurement, maintenance, enforcement and defense of Esperion's patents and proprietary rights; competitive conditions in the industry; business cycles affecting the markets in which any of Esperion's future products may be sold; extraordinary events and transactions; seeking and consummating business acquisitions, including the diversion of management's attention to the assimilation of the operations and personnel of any acquired business; fluctuations in foreign exchange rates; and economic conditions generally or in various geographic areas. Because all of the foregoing factors are difficult to forecast, you should not place undue reliance on any forward-looking statement. More detailed information about some of these and other risk factors is set forth in Esperion's filings with the Securities and Exchange Commission. Esperion does not intend to update any of these factors or to publicly announce the results of any revisions to any of these forward-looking statements other than as required under the federal securities laws.
SOURCE Pfizer Inc
Photo : A free corporate logo to accompany this story is available
Andy McCormick of Pfizer, +1-212-573-1226; or Frank Thomas of
Esperion, +1-734-222-1831
/Company News On-Call: http://www.prnewswire.com/comp/688250.htm
http://www.prnewswire.com
Copyright (C) 2003 PR Newswire. All rights reserved.
Ty Gigwoof,
I'm happy to be some help to this board.
When ppl are intesting lots $$ into a company it's nice to have a visual of their operation.I had no doubt that they were a REAL
company since Boston Scientific is in development with them.
But at the same time it's nice to know that they don't operate out of a suite at some old hotel motel.
I just might drop in there someday during regular business hrs and ask them more about their operation and where their headed.
Good Luck all the BIPH longs
BIPH DD
I live in Rochester ny where BIPH is located so I thought it would be a good idea to check them out first hand.
Biph is located in a Industrial Park that is still in development.When I pulled in the name on the sign said
Lennox Enterprise and there was no mention of Biophan Technologies that I could see,they do have a suite on the second floor I believe.
The building is L shaped and is quite new maybe a few years old at the most.The size of the building is about 50' feet x 100' long with and L @ the end most likely the loading dock.
It looked well maintained and plowed as well.
I was quite surprised @ 6 pm on a Sat there were 6-7 cars in the parking lot some nice cars volvo's and pathfinders and a new van.
I have no idea if anyone of Biophans staff were working but is a good sign that building is active.
Hope this helps any of you.
GOOD LUCK
I see IDNW had another great day.
Nice way to end the week :)
BIPH
I live in Rochester where their located
I'm going to check it out and drive by to see if they look like a class outfit.
Will update you BIPH longs soon what i find out.
SNNW~News
%PGAP %ALERT P%CBSA amex nyse nasdaq reuters P%SMR...
Printer version
December 17, 2003 06:30
Sun Network Group Inc.'s Subsidiary RTV Enters into Exclusive Arrangement with Sentinel America Corporation
Jump to first matched term
CORAL SPRINGS, Fla., Dec. 17, 2003 (PRIMEZONE) -- The Sun Network Group, Inc. (OTCBB:SNNW) (Berlin:SWK) announced here today that its wholly owned subsidiary, RadioTV Network, Inc. ("RTV"), has entered into an exclusive negotiating period with Sentinel America Corporation ("SAC") to merge and/or combine the television assets of RTV with SAC's American National Network ("ANN").
SNNW owns and operates Radio X, a new national radio network, in partnership with Sports Byline USA, and has been developing RTV since 1999 as a new television network that will produce and distribute TV versions of top rated radio programs. RTV has previously successfully test marketed its programs in Chicago and Pittsburgh.
ANN, established in 2001 and financed through a consortium of SAC investors, is a new television network that will program series, TV movies and documentaries of positive and constructive "Americana" themes. ANN is currently in production on "Dawn of the Nation," a multi-part series of the story of the American Revolution.
T. Joseph Coleman, CEO of SNNW, said: "We believe that combining our TV assets with ANN will significantly increase our current resources, enabling us to be more competitive in seeking and securing distribution for our channel and reduce infrastructure costs."
Michael Leighton, CEO of SAC added: "The RTV business model is an excellent one and the cross-promotional ability of its programming can also be amortized on ANN."
SNNW and SAC expect to conclude their arrangement in early 2004.
This announcement contains forward-looking statements about Sun Network Group, Inc., that may involve risks and uncertainties. Important factors relating to the company's operations could cause actual results to differ materially from those in forward- looking statements and are further detailed in filings with the Securities and Exchange Commission available at the SEC website (http://www.sec.gov). All forward-looking statements are based on information available to Sun Network Group, Inc. on the date hereof, and Sun Network Group, Inc., assumes no obligation to update such statements.
-0-
CONTACT: Sun Network Group, Inc.
(954) 360-4080
That sure was strange :)
I just added to my position.
Enjoy your lunch FF
One Rat down One last
Rat go Dow 11,000 here we go...
IMO
VPER ~ News
This one might be one to watch today
Good Luck today.
http://aolsvc.news.aol.com/news/article.adp?id=20031212083909990002
FF, yw
I will be watching NEOM and PJTG
Good Luck to you all today
MSGL New News
Beta testing
MSGL NEWS OUT
Testing complete.
RNKE
999 on the bid side
What about BIKO
Has something to do with Bio doesn't it?
and has been quiet lately
LBTT
I'm with some of you guys in at .002 out .0022
:(
AICI
Insiders own 60 % of company
and it can run to .28~.30 spreads will be .05 at times.